Multiple Cutaneous Squamous Cell Carcinoma Raises Risk of Recurrence, Metastasis
the Cancer Therapy Advisor take:
Patients with multiple cutaneous squamous cell carcinomas (CSCCs), especially those with 10 or more, have an elevated risk of local recurrence (LR) and nodal metastases (NM) compared to those with one CSCC, according to an article published online in the journal JAMA Dermatology.
The authors of this study analyzed electronic medical records of patients diagnosed with dermally invasive (non-in situ) primary CSCC between January 1, 2000, and December 31, 2009. The medical records were used to determine Brigham and Women’s Hospital tumor stage and outcomes such as LR, NM, and death due to CSCC.
A total of 985 patients were evaluated: 727 with 1 CSCC, 239 with 2 to 9 CSCCs, and 19 with 10 or more CSCCs. Most patients with 10 or more CSCCs (15 out of 19; 78.9%) were determined to be immunosuppressed.
Compared to patients with one CSCC, those with more than one had an increased risk of LR (subhazard ratio for 2-9 CSCCs, 1.8; 95% CI: 1.1, 4.3; and for ≥10 CSCCs, 3.8; 95% CI: 1.4, 10.0) and NM (subhazard ratio for 2-9 CSCCs, 3.0; 95% CI: 1.4, 6.5; and for ≥10 CSCCs, 4.2; 95% CI: 1.4, 10.4).
Patients with 10 or more CSCCs had a significantly higher 10-year cumulative incidence of LR and NM (LR, 36.8%; 95% CI: 19.2%, 59.0%; and NM, 26.3%; 95% CI: 11.8%, 48.8%) compared to the patients with two to nine CSCCs ( LR, 6.7%; 95% CI: 4.2%, 10.6%; and NM, 5.9%; 95% CI: 3.5%, 9.6%) and 1 CSCC (LR, 3.0%; 95% CI: 2.0%, 4.5%; and NM, 2.3%; 95% CI: 1.5%, 3.8%).
Patients with multiple cutaneous squamous cell carcinomas have elevated risk of local recurrence and nodal metastases.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models